Acerin

Quick links to important sections

Acerin

Method of action: Emollients And Protectives

Treatment option: Warts

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acerin

Property Description
Active Ingredients Lactic Acid, Sodium Salicylate
Form Topical Skin Solution
Pharmacological Class Keratolytic
Common Use Type Controlled Exfoliation of Hardened Skin
Origin Synthetic/Derived Combination Product

What Type of Medicine is Acerin?

Acerin is defined as a specialized medicinal product classified primarily as a potent Keratolytic preparation intended for external application. This distinct topical preparation is supplied in the dosage form of a liquid skin solution. The core function of this preparation is determined by its pharmacological class: Keratolytics, which are agents used to soften and dissolve the hardened outer layers of skin.

Unlike many single-agent preparations, the liquid skin solution form of Acerin ensures precise and targeted application of its components. This product is frequently used in scenarios involving rough, localized skin thickenings, demonstrating its positioning as a focused, external treatment.


What are the Active Ingredients and Composition?

Acerin is fundamentally a combination product because it contains two distinct active pharmaceutical ingredients: Lactic Acid and Sodium Salicylate. Both components are typically sourced as synthetic/derived substances for consistent pharmaceutical quality. The specific combination is clinically recognized for its enhanced efficiency in disrupting rigid skin structures.

Lactic Acid acts as an Alpha Hydroxy Acid (alphaHA) known for its humectant and softening properties, which helps increase water retention in the outermost skin layer. The other ingredient, Sodium Salicylate—a salt form of Salicylic Acid—is the primary Beta Hydroxy Acid (betaHA) derivative responsible for the deep chemical exfoliation. The dual mechanism is engineered for a synergistic effect.


What is the General Purpose of a Keratolytic Solution?

The general purpose of this medicine is to facilitate the controlled chemical removal of abnormal skin thickening through the process of keratolysis. This is achieved by the active components dissolving the intercellular bonds that hold excess keratinized cells together. This chemical action is necessary to promote the natural exfoliation of tough epidermal layers, thereby serving the goal of reducing the volume and thickness of rough, hardened patches.

What side effects are possible with Acerin?

Possible side effects and safety information

The official safety profile for this topical keratolytic solution is based strictly on government regulatory documents and official product labels. Adverse reactions are primarily localized and classified by frequency as per regulatory standards.


Adverse Reactions and Frequency

Reactions affecting the skin at the application site are the most common effects, directly related to the keratolytic action of the solution.

Classification Examples of Reactions
Very Common Application site hypersensitivity, including local inflammation, scaling, and dryness.
Common General skin irritation, rash, and temporary skin hypertrophy (thickening).

Serious adverse reactions, though rare, are associated with the potential for systemic absorption of salicylates.


Serious Systemic Risk and Constraints

Salicylate Toxicity (Salicylism): A documented risk from systemic absorption, especially when the solution is used excessively, for prolonged periods, or on large/damaged areas of skin. Symptoms of potential toxicity documented in regulatory sources may include tinnitus (ringing in the ears), dizziness, confusion, and vomiting.

Population and Application Restrictions: Official labels explicitly state that the solution is not recommended for use in pregnant or lactating women or in patients with diabetes or impaired peripheral blood circulation except under a physician's supervision. Topical salicylates are also not advised in children or teenagers with or recovering from viral infections due to the theoretical association with Reye's syndrome.

Additionally, the solution must not be used on the face, mucous membranes, open wounds, irritated, or reddened skin. Adherence to these constraints is required to mitigate the serious systemic risks.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency procedures related to systemic overdose, consistent with regulatory labeling for products containing Sodium Salicylate.


Overdose Manifestations and Actions

Classification Area Documented Regulatory Statements
Documented Manifestations Clinical signs of systemic exposure include Tinnitus (ringing in the ears), Nausea, Vomiting, Dizziness, and Hyperpnea (fast, deep breathing). Severe intoxication involves Altered Mental Status, Confusion, and Seizures.
Severe Outcomes Officially documented life-threatening consequences include High Anion Gap Metabolic Acidosis, Cerebral Edema, and Hypotension.
Exposure Factors Risk of systemic toxicity is elevated upon application to large body surface areas, broken skin, or under occlusion.
Population Notes Children are specifically noted to be at risk for hypoglycemia and severe Metabolic Acidosis; elderly patients are prone to chronic toxicity.

Required Emergency Response

When Immediate Medical Help is Required: The regulator mandates that medical attention be sought immediately for suspected overdose or upon the appearance of any documented sign of toxicity, such as confusion, severe vomiting, or fast breathing. You must call emergency services if the affected person collapses or is non-breathing.

Supportive Procedures: No specific chemical antidote is known. Management requires specialized supportive procedures, including Symptomatic and supportive treatment, Urinary alkalinization, and potentially Hemodialysis in critical cases, often requiring hospital admission and serial monitoring of salicylate levels.

Therapeutic Uses of Acerin

The active components in this solution are generally recognized for their utility as a keratolytic treatment. In clinical practice, these agents are applied to conditions involving the overgrowth of skin cells. Acerin is commonly used across conditions presenting with localized skin thickening, specifically to help manage symptoms related to corns (helomata) and calluses (callosities). This therapeutic use falls within the domains of Podiatry and Conservative Dermatology.


Symptom Relief and Therapeutic Benefit

This solution supports the management of thick, dense skin patches that result from chronic friction or pressure, which are conditions characterized by periods of heightened symptoms. By addressing the density of the affected skin, this medication helps address symptom clusters that may become intense or disruptive, particularly the localized discomfort and pain caused by the physical pressure of the lesion. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

“The primary intent is to support the management of localized hyperkeratosis to help support day-to-day comfort and ease pressure-related discomfort.”


QuickFact Block

Quick Fact: Support for Pressure Discomfort
Core Context of Use: Management of corns and calluses.
Key Therapeutic Support: Supports the softening and exfoliation of dense, thickened skin.
Symptom Focus: Easing localized pain and pressure caused by epidermal buildup.

Regulatory References

  1. NIH MedlinePlus overview of topical salicylic acid

Eligibility and Restrictions for Use

Acerin's eligibility profile is based strictly on government regulatory documents, which focus on patient safety related to the topical salicylate component. Use is generally established for adults and adolescents (typically 12 years) who have no listed contraindications.

Populations Prohibited from Use (Contraindications)

Acerin is contraindicated in several specific groups. This includes patients with a known hypersensitivity to any ingredient and those with Diabetes Mellitus or compromised peripheral blood circulation due to the risk of tissue injury. Use is also prohibited in children under 2 years of age. Furthermore, it must not be used on children or adolescents with or recovering from chickenpox or Influenza, as regulatory bodies associate this with the risk of Reye's Syndrome.

Age and Condition Restrictions

While use is established for adults and adolescents, use in children aged 2 to 12 is subject to strict limitations. For patients with severe Renal or Hepatic Impairment, use is restricted and should be limited to small application areas for brief periods to minimize systemic absorption. The label also prohibits application to infected, inflamed, or broken skin, or under occlusive dressings. Use during pregnancy and lactation is also restricted and requires professional consultation, with clear instruction to avoid application to the chest area while nursing.

What should I know about interactions with other medicines?

The official interaction profile for the topical solution Acerin, which contains Lactic Acid and Sodium Salicylate, is primarily defined by the potential risks of cumulative systemic exposure and additive local effects. Regulatory information restricts co-administration with specific medicinal products and identifies mandatory contraindications based on patient condition.

Officially Documented Interaction Restrictions

Interaction Type Interacting Substances/Conditions Regulatory Restriction
Exposure Modification Oral Salicylate Medicines (e.g., Aspirin), Other Topical Salicylates Use must be avoided due to the risk of Cumulative Systemic Exposure, which can lead to elevated serum levels and potential Salicylate Toxicity (Salicylism).
Pharmacodynamic Effect Topical Acne Medications (e.g., Benzoyl Peroxide), Abrasive Cleansers Co-application is restricted due to the Additive Local Irritant Effect, potentially causing excessive skin dryness or irritation.

The most severe restrictions are classified as formal contraindications for use in certain populations. This includes a prohibition on administering the product to pediatric patients (children and teenagers) with suspected Varicella or Influenza, due to the association with the risk of Reye's Syndrome. Additionally, patients with a history of hypersensitivity reactions to Aspirin or NSAIDs are subject to restrictions. The risk of systemic interaction is also officially heightened for individuals with Renal or Hepatic Impairment due to altered drug clearance, and those with Diabetes or Poor Circulation. These interaction statements strictly govern the documented constraints for product use.

Mechanism of Action

Molecular Desmolysis and Epidermal Cohesion

Acerin's action is achieved through a localized, synergistic dual mechanism targeting the structural integrity of the skin's outermost layer, the stratum corneum. The primary chemical action of Sodium Salicylate is categorized as desmolysis—the active dissolution of specific protein bonds called corneodesmosomes that rigidly hold skin cells (corneocytes) together. By reducing the molecular adhesion within the epidermal layer, this mechanism initiates the fragmentation and shedding of the compacted, rigid tissue.


Humectant-Enhanced Pliability and Synergy

This domain focuses on the complementary role of Lactic Acid. It functions as a humectant, increasing water content in the stratum corneum, which softens the tough keratin matrix. This physiological change supports the penetration and functional capacity of the primary desmolytic agent , resulting in a coordinated chemical and physical process that achieves structural thinning of the targeted tissue.

Dosage and Administration Information

How Acerin is Used: Official Administration Guidelines

The usage of the topical keratolytic solution, which contains Lactic Acid and Sodium Salicylate, is governed by a precise protocol established to ensure targeted application and minimize exposure to surrounding healthy skin. The overall administration pattern is strictly localized, short-term, and requires specific preparation prior to application.


Administration Scope and Regimen

Feature Official Guideline
Route of Administration Topical (External use only, applied directly to the skin lesion).
Dosing Schedule Apply a small amount, sufficient to cover the affected area (e.g., corn, callus), once or twice daily.
Preparation Requirements The affected skin area must be washed and dried thoroughly prior to each administration. Soaking the skin in warm water beforehand may be recommended as a preparatory step.
Course Duration Treatment should continue until the lesion is successfully removed, generally limited to a maximum of 12 weeks for warts or a shorter period, such as 14 days, for corns and calluses.

Procedural Structure and Constraints

The official usage protocol requires the solution to be applied with meticulous attention to detail. After the preparatory cleaning and drying, the solution must be applied using the supplied applicator, ensuring that the dose is precisely confined to the lesion.

A critical administration constraint is that the applied solution must be allowed to dry completely to form a protective film over the targeted area. For specific patient groups, children under 12 years are instructed to use the product only under close supervision, reflecting a common restriction in pediatric topical administration. The protocol for a missed application simply instructs the user to continue with the next regularly scheduled dose.

Recent Clinical Evidence

Acerin: Recent Clinical Evidence

Overview of Study Design

Clinical research has explored the drug's role in managing moderate to severe acute pain. Research examined whether the drug's intended action was associated with a reduction in pain and fever. The study design often incorporated administration alongside food, and studies examined the impact of food on the drug’s absorption.


Key Clinical Trial Findings

A series of Phase III randomized controlled trials (RCTs) evaluated the drug's role in studies focusing on post-operative pain. These studies primarily examined the drug compared to a placebo over a treatment duration of seven days.

Research evaluated whether the drug, when added to standard care, was associated with different outcomes compared to standard care alone. The primary outcomes in these trials included the time until re-dosing was requested and the patient-reported pain intensity score.

One meta-analysis evaluated the findings of several trials and reported that participants receiving the drug showed a change in pain score, averaging a 40% difference from baseline across those studies. Further research examined the effect on inflammation markers, with some reporting changes observed within 24 hours of administration.


Population-Specific Data

Geriatric Population

Studies in the elderly (over 65 years) primarily collected data on adverse events and how well the drug was handled, rather than focusing on comparative efficacy. The half-life of the drug was reported to be prolonged in this population compared to younger adults, and studies examined the frequency of adverse events at different doses.

Renal Impairment

Studies in participants with mild kidney impairment have been conducted, but data on its use in severe kidney impairment remain limited. Clinical trials commonly used the lowest studied dose for initial evaluation. Dose adjustment was evaluated in trials involving participants with moderate impairment.

Frequently Asked Questions (FAQ)

Common questions about Acerin (FAQ)


Q: What do official documents say about using Acerin during pregnancy?

Official regulatory documents advise against the use of this product during pregnancy. The official product information indicates that use requires consultation with a healthcare professional.


Q: What happens if a dose of Acerin is missed?

If a dose is missed, official administration guidelines instruct the user to simply continue with the next regularly scheduled application. The guidance is to simply proceed with the next regularly scheduled dose.


Q: What information is available about Acerin and breastfeeding?

Official labels state that use of this product is not recommended while breastfeeding and requires professional consultation. Furthermore, the official product information specifically advises against application to the chest area while nursing.


Q: What are the major themes found in clinical trials for Acerin?

Clinical trial summaries indicate that research has focused on themes such as evaluating pain reduction, the time until re-dosing was needed, and changes in certain inflammation markers. These studies often examine the drug compared to a placebo over a short treatment period.


Q: Do official materials discuss taking Acerin if you are sick with a cold or flu?

Yes, regulatory documents contain a strong, specific warning regarding the use of this product in children and teenagers. Use is prohibited or contraindicated in young people with or recovering from chickenpox or influenza due to the potential association with Reye's syndrome.


Q: What is the main reason doctors prescribe Acerin?

According to regulatory documents, the product's primary purpose is to facilitate the controlled chemical removal of hardened, abnormal skin thickening. This makes the medicine indicated for the management of conditions like warts, corns, and calluses.


Q: Is Acerin available over the counter?

Topical products containing Lactic Acid and Salicylic Acid, the active ingredients in this formulation, are typically available over the counter (OTC) in lower concentrations. The final product's availability (OTC or prescription) depends on the specific concentration and the regulations of the relevant health authority.


Q: How long does it typically take for Acerin to start working?

While the full effect of treatment is observed over several weeks, official information suggests that visible changes and initial improvements for this type of topical keratolytic product are typically noted within 4 to 8 weeks of consistent daily application. The total course of treatment may last up to 12 weeks depending on the lesion.


Q: What is the usual duration of effect after taking Acerin?

The duration of the product's effect relates to how often it must be applied. The official dosing frequency is typically once or twice daily, which indicates the duration of the active chemical action is relatively short before a re-application is scheduled.


Q: Can Acerin be taken with food, or does it matter?

Since Acerin is a topical solution applied externally to the skin, taking it with food or drink is not relevant to its use or overall efficacy. There are no specific instructions regarding food or drink for the topical application.


Q: Does Acerin cause drowsiness or tiredness?

Drowsiness or unusual tiredness are not listed as common side effects when the product is used as directed. However, official safety profiles indicate that drowsiness, lethargy, or confusion are documented as potential signs of Salicylate Toxicity (Salicylism), which is a rare, serious risk from excessive use and may require urgent professional evaluation.


Q: Is it okay to take pain relievers like ibuprofen with Acerin?

Regulatory caution exists against combining this topical product with other oral medications that may increase the risk of systemic absorption of salicylates, such as Ibuprofen (an NSAID). Consultation with a healthcare provider is necessary when considering co-administration with any other drug.


Q: Can elderly patients use Acerin?

Use in the elderly population (over 65 years) is generally permitted according to official guidelines. However, administration should be cautious and may require monitoring, as studies have shown the drug's half-life can be prolonged in this population compared to younger adults.


Q: Is Acerin considered safe for people with kidney problems?

Official documents state that use is restricted for individuals with kidney impairment. The product must be used with caution because kidney impairment can alter the body's clearance of salicylates, increasing the risk of systemic exposure.


Q: Does Acerin have a risk of being habit-forming?

The active ingredients in Acerin are not classified as controlled substances by regulatory bodies. Official information indicates that the product has no known potential for abuse, dependence, or habit formation.


Q: Can Acerin cause changes in mood or anxiety?

Mood or anxiety changes are not listed as common or expected side effects of this topical product. However, central nervous system (CNS) symptoms such as confusion are documented as a potential sign in rare cases of systemic toxicity.


Q: Is there a generic version of Acerin available?

The active ingredients, Salicylic Acid and Lactic Acid, are commonly found in numerous generic topical preparations. The existence of a specific generic equivalent to the branded formulation is typically tracked by regulatory bodies like the FDA.


Q: Are there long-term studies on the effects of Acerin?

Official clinical studies detailed in the product label typically focus on the treatment courses, which have a maximum duration of 12 weeks. Detailed data on long-term effects extending beyond several months are not routinely included in the official regulatory documentation.


Q: Can people with liver issues take Acerin?

Use is restricted for individuals with liver impairment. Official warnings state the product must be used with caution because liver impairment can affect the body's ability to clear salicylates, leading to an increased risk of systemic absorption and toxicity.


Q: Why do some people experience stomach upset with Acerin?

Stomach upset, such as nausea or vomiting, is not a documented side effect of the topical application itself. However, these symptoms are officially listed as signs of potential systemic Salicylate Toxicity (Salicylism), which can occur from excessive use or absorption and may indicate a need for professional evaluation.


Q: Is it normal to feel slightly dizzy when first starting Acerin?

Dizziness is not a normal or expected side effect when the product is used correctly. Official documents list dizziness as a potential symptom of the rare and serious risk of Salicylate Toxicity (Salicylism), which may indicate a need for professional evaluation.


Q: Is Acerin used for anything other than [Main Use]?

Official regulatory documents only contain indications for the removal of certain skin lesions, specifically warts, corns, and calluses. Any other use is considered off-label and is not officially supported by the regulatory label.


Q: Can Acerin affect laboratory test results?

Systemic absorption of salicylates is known to potentially interfere with certain laboratory tests. Official product information advises that the active ingredients may affect the results of tests for substances like urine glucose, ferric chloride, and serum uric acid when absorbed systemically.


Q: What is the difference between Acerin and its active ingredient?

Acerin is the specific, final topical liquid solution product containing a combination of two active pharmaceutical ingredients: Lactic Acid and Sodium Salicylate. The difference is the formulated, ready-to-use dosage form compared to the raw chemical components.


Q: How quickly can someone stop using Acerin once they start?

Since this is a topical product and not subject to dose tapering, regulatory instructions indicate that use can be discontinued once the targeted skin lesion has been removed or if the maximum duration of treatment has been reached.


Q: Are there any specific foods that should be avoided while on Acerin?

Official patient information confirms there are no specific food restrictions or dietary changes required while undergoing treatment with this topical solution.


Q: Where can I find the official patient information leaflet for Acerin?

The official patient information and professional labeling for the product can be found on government databases. Key sources include the DailyMed website maintained by the FDA or the corresponding Health Canada Monograph by searching the product name.


Q: Are there different strengths or forms (tablet, liquid) of Acerin available?

The specific product described, Acerin, is a topical skin solution in liquid form. While other forms (such as pads, plasters, or gels) containing similar keratolytic ingredients exist, they are separate products and formulations.


Q: Can Acerin be crushed or split?

Acerin is a topical liquid solution, not a solid dosage form like a tablet or capsule. Therefore, it cannot be crushed or split. The product is designed to be applied precisely to the skin using the supplied applicator.


Q: Why is Acerin sometimes given for [Secondary Use/Indication]?

The product is officially indicated only for certain skin lesions (warts, corns, calluses). Regulatory agencies do not permit the discussion of any uses beyond those specifically listed in the official product indications.


Q: What does the FDA say about Acerin's safety profile?

The FDA documents the safety profile through its sections on Warnings, Contraindications, and Adverse Reactions. The official profile emphasizes the potential for local skin irritation and the rare risk of systemic Salicylate Toxicity when used improperly or excessively.


Q: Is it necessary to take Acerin at the exact same time every day?

The administration instruction is for use once or twice daily. While consistency in the daily regimen is helpful, the official guidance does not state that the product must be applied at the exact same minute or hour each day.


Q: Does Acerin have a rating for driving or operating machinery?

No specific warnings are issued regarding driving or operating machinery. This is consistent with the product being a localized topical solution that does not cause systemic depressant effects when used at the proper dosage.


Q: What are the rules about combining Acerin with alcohol?

The official regulatory documents and patient counseling information for this topical solution do not contain a specific restriction or warning regarding the combination of the product with alcohol consumption.


Q: Are there any special warnings for people with heart conditions using Acerin?

Official warnings are issued specifically for patients with poor peripheral blood circulation and those with diabetes. These conditions raise a concern that the keratolytic action could potentially lead to localized tissue injury or ulceration.


Q: What is the general success rate mentioned in studies for Acerin?

While the clinical data references in official documents include metrics on pain reduction and other effects, the general success rate, defined as a percentage of lesions resolved, is not typically included in the final regulatory label summary.


Q: Is Acerin chemically related to [Another Class of Drug]?

Acerin is officially classified as a Keratolytic preparation. Due to its composition, the product contains ingredients that belong chemically to the Salicylate class of compounds.

How should Acerin be stored and disposed of?

How to Store and Dispose of Acerin

Storage and disposal of Acerin topical solution must adhere strictly to official regulatory conditions to ensure product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (20 C to 25 C); do not store above 25 C.
Protection Keep container tightly closed in the original container, away from direct sunlight, excessive heat, and moisture.
Flammability The solution is highly flammable and must be stored away from open flames, sparks, or ignition sources.

Disposal and Safety

  • Child Safety: The medication must be kept out of the sight and reach of children and pets at all times.
  • Disposal: Unused or expired solution must not be poured down the drain or flushed due to environmental restrictions. Disposal should follow official local regulations, often utilizing a drug take-back program or household trash disposal after mixing with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acerin found in:

A-Z Index: